ABSTRACT
A total of 480 newly weaned pigs (PIC 337 × 1050; Genus, Hendersonville, TN) with an initial body weight (BW) of 6.20â ±â 0.61 kg were used in a dose-response study to investigate the impact of increasing standardized ileal digestible (SID) Arg:Lys on nursery pig growth performance. At weaning, pigs were placed into 48 pens with 5 barrows and 5 gilts per pen. Pens were randomly assigned to 1 of 6 dietary treatments. The experimental diets were formulated with increasing SID Arg:Lys, achieved by substituting corn starch, glycine, and l-alanine with l-arginine, resulting in SID Arg:Lys ranging from 45% to 145%. Diets were sublimiting in SID Lys and exceeded all other essential amino acid requirements. The experimental diets were fed across two feeding phases from days 0 to 10 and 10 to 27, with adjustments made to account for the Lys requirement of the pigs. All pens were placed on a common diet for the remaining 14 d of the study to evaluate carryover effects. Pigs and feeders were weighed at the start and end of each phase to calculate average daily gain (ADG), average daily feed intake (ADFI), and feed efficiency (G:F). Data were analyzed according to a linear regression model, which included the linear and quadratic effects of SID Arg:Lys and initial BW. Pen was the experimental unit, and results were considered significant at Pâ ≤â 0.05 and a tendency at 0.50â <â Pâ ≤â 0.10. From days 0 to 27, Arg:Lys tended to have a quadratic effect on ADFI (Pâ =â 0.058), where 97.00â ±â 7.631% SID Arg:Lys maximized feed intake. Similarly, Arg:Lys had a quadratic impact on ADG (Pâ =â 0.046), where ADG was maximized at a SID Arg:Lys of 95.65â ±â 7.165. Correspondingly, Arg:Lys had a quadratic effect on pig BW on day 27 (Pâ =â 0.014). These effects were carried through the end of the study, where Arg:Lys quadratically impacted days 0 to 41 ADFI (Pâ =â 0.006), ADG (Pâ =â 0.077), and day 41 BW (Pâ =â 0.028). There was no evidence of an effect of SID Arg:Lys on G:F throughout the study (Pâ ≥â 0.315). In conclusion, SID Arg:Lys quadratically impacted ADFI and ADG in 6- to 13-kg nursery pigs, where ADFI was maximized at a SID Arg:Lys of 97.00% (95% CI [81.6%, 112.4%]), and ADG was maximized at a SID Arg:Lys of 95.65% (95% CI [81.2%, 110.1%]). Together, these data suggest that the SID Arg:Lys requirement of nursery pigs is at least 81%, based on the lower bounds of the 95% CI for maximum ADG and ADFI, and excessive Arg supplementation may negatively affect growth performance.
Arginine is considered a conditionally essential amino acid (EAA) in swine, meaning that under certain circumstances, the rate of Arg utilization is greater than endogenous synthesis, resulting in a dietary Arg requirement to meet the pig's needs for growth and other biological functions. Our group and others have shown benefits to feeding Arg levels above the NRC (2012) estimated requirement; however, there has been a lack of research to determine the SID Arg requirement relative to lysine in young pigs. Therefore, the objective of this study was to determine the optimal dietary SID Arg:Lys to maximize growth performance in 6- to 13-kg nursery pigs. In the current trial, average daily gain (ADG) and average daily feed intake (ADFI) responded quadratically to increasing SID Arg:Lys from 45% to 145%, where ADFI was maximized at a SID Arg:Lys of 97.00% (95% CI [81.6%, 112.4%]) and ADG was maximized at 95.65% (95% CI [81.2%, 110.1%]). Together, the results of this study suggest the SID Arg:Lys requirement of 6- to 13-kg nursery pigs is at least 81%, based on the lower bounds of the 95% confidence intervals for maximum ADG and ADFI, but excess supplementation may reduce performance.
Subject(s)
Animal Feed , Animal Nutritional Physiological Phenomena , Arginine , Diet , Lysine , Animals , Arginine/pharmacology , Arginine/administration & dosage , Diet/veterinary , Animal Feed/analysis , Lysine/administration & dosage , Lysine/pharmacology , Male , Female , Swine/growth & development , Swine/physiology , Ileum/physiology , Ileum/drug effects , Digestion/drug effects , Random Allocation , Dietary Supplements/analysis , Weight Gain/drug effectsABSTRACT
PURPOSE: Weight regain after metabolic bariatric surgery is a common problem. Food addiction is an eating disorder that can be one of the reasons for weight regain in these patients. This study aimed to evaluate the effects of probiotic supplementation with a weight loss program and cognitive behavioral therapy (CBT) on anthropometric measures, eating behavior, food addiction, and related hormone levels, in patients with food addiction and weight regain after metabolic bariatric surgery. MATERIALS AND METHODS: This randomized, triple-blind, placebo-controlled clinical trial was conducted on patients with food addiction and weight regain after metabolic bariatric surgery. Participants (n = 50) received a weight loss program and CBT plus probiotic, or placebo for 12 weeks. Then, anthropometric measurements, biochemical markers, eating behavior, and food addiction were assessed. RESULTS: Weight and body mass index (BMI) decreased significantly in the probiotic group compared to placebo (p = 0.008, p = 0.001, respectively). Fat mass was significantly decreased in the probiotic group (p < 0.001). Moreover, a significant improvement was observed in the probiotic group's eating behavior and food addiction compared to the placebo group (p < 0.001). Serum levels of leptin decreased significantly (p = 0.02), and oxytocin serum levels increased significantly (p = 0.008) in the probiotic group compared to the placebo group. CONCLUSION: Adding probiotic supplements to the weight loss program and CBT is superior to the weight loss program and CBT alone in improving weight loss, eating behavior, and food addiction in patients with food addiction and weight regain after metabolic bariatric surgery.
Subject(s)
Bariatric Surgery , Body Composition , Cognitive Behavioral Therapy , Feeding Behavior , Food Addiction , Obesity, Morbid , Probiotics , Weight Gain , Humans , Female , Male , Probiotics/therapeutic use , Adult , Obesity, Morbid/surgery , Obesity, Morbid/therapy , Obesity, Morbid/blood , Food Addiction/therapy , Weight Reduction Programs , Middle Aged , Weight Loss/physiology , Treatment Outcome , Body Mass Index , Dietary Supplements , Ghrelin/blood , Combined Modality Therapy , Leptin/bloodABSTRACT
This experiment was designed to investigate the effect of feeding wheat-straw based densified complete feed block (DCFB) on daily weight gain, feed intake, digestibility and feed conversion rate in growing heifer calves. Eight weaned F1 Frisian*Borena (Bos taurus × Bos indicus) crossbred calves (92.5 ± 27.5 kg body weight) and 5 months of age were randomly distributed into four groups, each with two animals evaluated under 4 × 4 double Latin Square Design for 240 days. The control treatment was natural pasture hay (NPH) and concentrate mix (CM) fed conventionally in a way that covers 50:50% requirements on dry matter (DM) bases and DCFB prepared by mixing wheat straw (WS) to concentrates mixture in the ratio of 50:50 (T2), 40:60 (T3) and 30:70 (T4), respectively. Each heifer group was fed on each diet for 60 days. At the end of each period the last 7 days were used to collect feed and feacal samples. However, the heifers were weighed each 15 days to estimate daily growth performances. It was found that significant (P < 0.05) differences among groups in average daily gain, feed conversion rate, feed intake and digestibility. The densification of WS and feeding in the form of feed block generally improved feed DM and nutrient intake and digestibility. The increase in the proportion of CM in the DCFBs also increased the DM and nutrient intake and digestibility. Heifer growth rate was higher (P < 0.05) in T1, T3 and T4 diets than T2 groups. Feed conversion ratio was higher (P < 0.05) both in T3 and T4 compared to T1 and T2. The total cost of production per each gram body weight gained was recorded higher (P < 0.05) for calves in the T2 group compared to calves in T1, T3 and T4. In conclusion, maintaining post weaned F1 heifer calves on DCFB composed of wheat straw and a commercial calf's concentrate based diet in the ratio of 40 to 60 would both biologically and economically feasible.
Subject(s)
Animal Feed , Diet , Digestion , Triticum , Weight Gain , Animals , Cattle/growth & development , Cattle/physiology , Animal Feed/analysis , Female , Diet/veterinary , Animal Nutritional Physiological Phenomena , Random Allocation , WeaningABSTRACT
South Asians (SAs) develop type 2 diabetes at lower body mass index values than white Europeans (WEs). This basic human experimental study aimed to compare the metabolic consequences of weight gain in SA and WE men without overweight or obesity. Fourteen SAs and 21 WEs had assessments of body composition, metabolic responses to mixed-meal ingestion, cardiorespiratory fitness and physical activity, and a subcutaneous abdominal adipose tissue biopsy, before and after 4-6 weeks of overfeeding to induce 5-7% weight gain. Here we show that body mass index and whole-body adipose tissue volume increases similarly between ethnic groups, but SAs gain less lean tissue. SAs experience a substantially greater decrease in insulin sensitivity compared with WEs (38% versus 7% decrease, P = 0.009), have fewer small (37.1% versus 60.0%, P = 0.003) and more large (26.2% versus 9.1%, P = 0.005) adipocytes at baseline and have a smaller decrease in very small adipocytes with weight gain (-0.1% versus -1.9%, P < 0.0001). Ethnic differences in adipocyte morphology are associated with SA's greater adverse metabolic changes with weight gain. ClinicalTrials.gov registration: NCT02399423 .
Subject(s)
Asian People , Body Composition , Weight Gain , White People , Humans , Male , Adult , Body Mass Index , Insulin Resistance , Middle Aged , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/etiology , Adipocytes/metabolismABSTRACT
Consumption of palatable food (PF) can alleviate anxiety, and pain in humans. Contrary, spontaneous withdrawal of long-term PF intake produces anxiogenic-like behavior and abnormal pain sensation, causing challenges to weight-loss diet and anti-obesity agents. Thus, we examined α7-nicotinic acetylcholine receptors (α7nAChR) involvement since it plays essential role in nociception and psychological behaviors. METHODS: Adult male C57BL/6 mice were placed on a Standard Chow (SC) alone or with PF on intermittent or continuous regimen for 6 weeks. Then, mice were replaced with normal SC (spontaneous withdrawal). Body weight, food intake, and calories intake with and without the obesogenic diet were measured throughout the study. During PF withdrawal, anxiety-like behaviors and pain sensitivity were measured with PNU-282987 (α7nAChR agonist) administration. RESULTS: Six weeks of SC + PF-intermittent and continuous paradigms produced a significant weight gain. PF withdrawal displayed hyperalgesia and anxiety-like behaviors. During withdrawal, PNU-282987 significantly attenuated hyperalgesia and anxiety-like behaviors. CONCLUSION: The present study shows that a PF can increase food intake and body weight. Also, enhanced pain sensitivity and anxiety-like behavior were observed during PF withdrawal. α7nAChR activation attenuated anxiolytic-like behavior and hyperalgesia in PF abstinent mice. These data suggest potential therapeutic effects of targeting α7 nAChRs for obesity-withdrawal symptoms in obese subjects.
Subject(s)
Anxiety , Benzamides , Bridged Bicyclo Compounds , Hyperalgesia , Mice, Inbred C57BL , Obesity , alpha7 Nicotinic Acetylcholine Receptor , Animals , alpha7 Nicotinic Acetylcholine Receptor/metabolism , Male , Anxiety/etiology , Hyperalgesia/etiology , Hyperalgesia/metabolism , Benzamides/pharmacology , Benzamides/administration & dosage , Obesity/psychology , Obesity/metabolism , Bridged Bicyclo Compounds/pharmacology , Mice , Eating/drug effects , Behavior, Animal/drug effects , Weight Gain/drug effectsABSTRACT
This study investigated the impact of feeding 17% moringa leaf meal (MLM) on the ruminal and fecal microbial composition and body weight gain (BWG) performance of lambs (Ovis aries) and kids (Capra hircus). A total of n = 28 lambs (n = 14, no-moringa, n = 14, 17% moringa) and 24 kids (n = 12, no-moringa, n = 12, 17% moringa) were involved in the experiment and body weight was recorded fortnightly. Metagenomic shotgun sequencing was performed on 28, 22, and 26 ruminal solid, liquid fraction, and fecal samples from lambs, and 23, 22, and 23 samples from kids. Moringa supplementation significantly increased BWG in lambs (21.09 ± 0.78 to 26.12 ± 0.81 kg) and kids (14.60 ± 1.29 to 18.28 ± 1.09 kg) (p-value ≤ 0.01). Microbiome analysis revealed an elevated Firmicutes:Bacteroidetes ratio in the moringa diet group. Moringa-fed animals exhibited increased microbial genera associated with volatile fatty acids (VFAs) production (Prevotella, Anaerovibrio, Lachnospiraceae, Butyrivibrio, Christensenella) and starch and fiber digesters (Proteobacteria, Ruminococcus). The increase in the bacterial genus Sharpea suggested possible methane reduction and decreased proportion of pathogens, Aliarcobacter_ID28198, Campylobacter_ID194 and Campylobacter_ID1660076 suggest health benefits. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis demonstrated significant alterations in microbial gene pool and metabolic pathways related to carbohydrate, protein, lipid and energy metabolism, indicating potential improvements in animal health. Overall, moringa feeding showed higher energy recovery, improved growth, and potential benefits in methane reduction and reduced pathogenic bacteria.
Subject(s)
Animal Feed , Feces , Gastrointestinal Microbiome , Goats , Moringa , Plant Leaves , Animals , Gastrointestinal Microbiome/drug effects , Animal Feed/analysis , Moringa/chemistry , Sheep , Feces/microbiology , Dietary Supplements , Fatty Acids, Volatile/metabolism , Rumen/microbiology , Bacteria/classification , Bacteria/genetics , Bacteria/isolation & purification , Bacteria/metabolism , Weight Gain/drug effects , Diet/veterinary , MetagenomicsABSTRACT
Genetic improvement of local rabbit breeds using modern approaches such as marker-assisted selection requires accurate and precise information about markerâtrait associations in animals with different genetic backgrounds. Therefore, this study was designed to estimate the association between two mutations located in the Neuropeptide Y (NPY, g.1778G > C) and Phosphoglycerate Mutase 2 (PGAM2, c.195 C > T) genes in New Zealand White (NZW), Baladi (BR), and V-line rabbits. The first mutation was genotyped using high-resolution melting, and the second mutation was genotyped using the PCR-RFLP method. The results revealed significant associations between the NPY mutation and body weight at 10 (V-line) and 12 weeks of age (NZW, BR, and V-line), body weight gain (BWG) from 10 to 12 weeks of age (BR), BWG from 6 to 12 weeks of age (NZW, BR, and V-line), average daily gain (NZW, BR, and V-line, and BR), growth rate (GR) from 8 to10 weeks (V-line), 10 to 12 weeks (BR), and GR from 6 to 12 weeks of age (BR, and V-line). The PGAM2 mutation was associated with body weight at 10 (V-line) and 12 (NZW, and V-line) weeks of age, with significant positive additive effects at 12 weeks of age in all breeds, and was associated with BWG from 8 to 10 and 10 to 12 in BR, and BWG from 6 to 12 weeks of age (NZW, and BR), and average daily gain (NZW, and BR), and was associated with GR form 8 to 10 weeks (BR), from10 to 12 weeks (BR, and V-line) and from 6 to 12 weeks (BR). The results highlighted the importance of the two mutations in growth development, and the possibility of considering them as candidate genes for late growth in rabbits.
Subject(s)
Neuropeptide Y , Phosphoglycerate Mutase , Polymorphism, Single Nucleotide , Animals , Rabbits/growth & development , Rabbits/genetics , Phosphoglycerate Mutase/genetics , Phosphoglycerate Mutase/metabolism , Neuropeptide Y/genetics , Neuropeptide Y/metabolism , Male , Female , Genotype , Body Weight/genetics , Polymorphism, Restriction Fragment Length , Weight Gain/geneticsABSTRACT
Pork is one type of the most frequently consumed meat with about 30% globally. Thus, the questions regarding to the health effects of diet with high fat content from lard are raised. Here, we developed a model of mice fed with high fat (HF) from lard to investigate and have more insights on the effects of long-time feeding with HF on health. The results showed that 66 days on HF induced a significant gain in the body weight of mice, and this weight gain was associated to the deposits in the white fat, but not brown fat. The glucose tolerance, not insulin resistance, in mice was decreased by the HF diet, and this was accompanied with significantly higher blood levels of total cholesterol and triglycerides. Furthermore, the weight gains in mice fed with HF seemed to link to increased mRNA levels of adipose biomarkers in lipogenesis, including Acly and Acaca genes, in white fat tissues. Thus, our study shows that a diet with high fat from lard induced the increase in body weight, white fat depots' expansion, disruption of glucose tolerance, blood dyslipidemia, and seemed to start affecting the mRNA expression of some adipose biomarkers in a murine model.
Subject(s)
Biomarkers , Diet, High-Fat , Dietary Fats , RNA, Messenger , Animals , Mice , Diet, High-Fat/adverse effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Biomarkers/metabolism , Biomarkers/blood , Male , Dietary Fats/metabolism , Insulin Resistance , Adipose Tissue/metabolism , Body Weight , Mice, Inbred C57BL , Weight Gain , Adipose Tissue, White/metabolism , Triglycerides/blood , Triglycerides/metabolismABSTRACT
INTRODUCTION: Dolutegravir (DTG)-based antiretroviral therapy is the World Health Organization's preferred first-line regimen for all persons with HIV, including pregnant women. While DTG has been implicated as an obesogen associated with greater weight gain compared to other antiretrovirals, there is a paucity of data in pregnant women and their children. The Obesogenic oRigins of maternal and Child metabolic health Involving Dolutegravir (ORCHID) study is investigating associations between DTG, weight gain, and metabolic outcomes in the context of HIV. MATERIALS & METHODS: ORCHID is a prospective observational study taking place in Cape Town, South Africa (NCT04991402). A total of 1920 pregnant women with and without HIV infection are being followed from ≤18 weeks gestational age to 24 months postpartum with their children. Participants attend eleven study visits: 3 antenatal, delivery, and 7 postnatal visits. Several embedded sub-studies address specific scientific aims. Primary outcome measurements in mothers include anthropometry, blood pressure, body composition, dysglycemia, insulin resistance (IR), and dyslipidemia. Other maternal measures include demographics, resting energy expenditure, viral load, physical activity, dietary intake, hepatic steatosis, and repository specimens. Sub-study measurements include markers of adipose inflammation, gut integrity, and satiety/hunger, subcutaneous adipose tissue morphology and mitochondrial function, and metabolomics. Primary outcome measurements in children include anthropometry, adipose tissue mass, dysglycemia, IR, and dyslipidemia. Other variables include fetal growth, birth outcomes, medical/breastfeeding history, caloric intake, neurodevelopment, and repository specimens. Sub-study measurements include metabolites/lipid subspecies in umbilical cord blood, as well as breast milk composition and DTG exposure. DISCUSSION: ORCHID will play a pivotal role in defining obesogenic mechanisms and clinical consequences of DTG use in pregnancy in women with HIV and their children. It will provide insights into metabolic disease risk reduction in the context of HIV/DTG, identify intervention targets, and inform public health approaches to diminish chronic metabolic co-morbidities for women and children.
Subject(s)
HIV Infections , Heterocyclic Compounds, 3-Ring , Oxazines , Piperazines , Pyridones , Humans , Female , Pregnancy , HIV Infections/drug therapy , Heterocyclic Compounds, 3-Ring/adverse effects , Heterocyclic Compounds, 3-Ring/therapeutic use , Piperazines/adverse effects , Piperazines/therapeutic use , Adult , Pregnancy Complications, Infectious/drug therapy , Pregnancy Complications, Infectious/virology , Prospective Studies , HIV Integrase Inhibitors/adverse effects , HIV Integrase Inhibitors/therapeutic use , Child, Preschool , Infant , Infant, Newborn , Obesity/chemically induced , Obesity/epidemiology , Insulin Resistance , Male , Weight Gain/drug effects , Cohort Studies , South Africa/epidemiologyABSTRACT
BACKGROUND: Dyslipidemia increases cardiovascular disease risk, the leading cause of death worldwide. Under time-restricted feeding (TRF), wherein food intake is restricted to a consistent window of <12 hours, weight gain, glucose intolerance, inflammation, dyslipidemia, and hypercholesterolemia are all reduced in mice fed an obesogenic diet. LDLR (low-density lipoprotein receptor) mutations are a major cause of familial hypercholesterolemia and early-onset cardiovascular disease. METHODS: We subjected benchmark preclinical models, mice lacking LDLR-knockout or ApoE knockout to ad libitum feeding of an isocaloric atherogenic diet either ad libitum or 9 hours TRF for up to 13 weeks and assessed disease development, mechanism, and global changes in hepatic gene expression and plasma lipids. In a regression model, a subset of LDLR-knockout mice were ad libitum fed and then subject to TRF. RESULTS: TRF could significantly attenuate weight gain, hypercholesterolemia, and atherosclerosis in mice lacking the LDLR-knockout mice under experimental conditions of both prevention and regression. In LDLR-knockout mice, increased hepatic expression of genes mediating ß-oxidation during fasting is associated with reduced VLDL (very-low-density lipoprotein) secretion and lipid accumulation. Additionally, increased sterol catabolism coupled with fecal loss of cholesterol and bile acids contributes to the atheroprotective effect of TRF. Finally, TRF alone or combined with a cholesterol-free diet can reduce atherosclerosis in LDLR-knockout mice. However, mice lacking ApoE, which is an important protein for hepatic lipoprotein reuptake do not respond to TRF. CONCLUSIONS: In a preclinical animal model, TRF is effective in both the prevention and regression of atherosclerosis in LDLR knockout mice. The results suggest TRF alone or in combination with a low-cholesterol diet can be a lifestyle intervention for reducing cardiovascular disease risk in humans.
Subject(s)
Atherosclerosis , Disease Models, Animal , Liver , Mice, Knockout, ApoE , Receptors, LDL , Animals , Receptors, LDL/genetics , Receptors, LDL/deficiency , Atherosclerosis/prevention & control , Atherosclerosis/genetics , Atherosclerosis/metabolism , Atherosclerosis/etiology , Liver/metabolism , Male , Mice, Inbred C57BL , Time Factors , Fasting/blood , Mice , Hypercholesterolemia/genetics , Hypercholesterolemia/metabolism , Hypercholesterolemia/complications , Diet, Atherogenic , Weight Gain , Mice, Knockout , Aortic Diseases/prevention & control , Aortic Diseases/genetics , Aortic Diseases/pathology , Aortic Diseases/metabolism , Lipids/blood , Apolipoproteins EABSTRACT
BACKGROUND: Epidemiological evidence on weight change and atrial fibrillation (AF) remains limited and inconsistent. Previous studies on body mass index (BMI) in youth and AF rarely considered subsequent BMI. This study aimed to assess the associations of AF with weight change and BMI in youth, as well as modified effect by genetic susceptibility of AF. METHODS: The study included 21,761 individuals (mean age 57.8 years) from the Malmö Diet and Cancer cohort. Weight information was obtained at three time points, including recalled weight at age 20 years, measured weight at baseline (middle adulthood), and reported weight at 5-year follow-up examination (late middle adulthood). A weighted genetic risk score of AF was created using 134 variants. RESULTS: During a median follow-up of 23.2 years, a total of 4038 participants developed AF. The association between weight change from early to middle adulthood and AF risk was modified by sex (Pinteraction = 0.004); weight loss was associated with a lower AF risk in females, but not in males. Conversely, weight gain was positively associated with AF risk in a linear manner in females, whereas increased AF risk appeared only when weight gain exceeded a threshold in males. Participants with weight gain of > 5 kg from middle to late middle adulthood had a 19% higher risk of AF relative to those with stable weight, whereas weight loss showed a null association. Compared to individuals with a lower BMI at age 20 years, those with a BMI above 25 kg/m2 had an increased risk of AF (HR = 1.14; 95% CI: 1.02-1.28), after controlling for baseline BMI; this association was more pronounced in males or those with a lower genetic risk of AF. CONCLUSIONS: Weight gain in middle adulthood was associated with higher AF risk. Weight loss from early to middle adulthood, but not from middle to late middle adulthood, was associated with a lower risk of AF only in females. Higher BMI in youth was associated with an increased risk of AF, particularly among males or those with a lower genetic risk of AF.
Subject(s)
Atrial Fibrillation , Body Mass Index , Genetic Predisposition to Disease , Weight Gain , Humans , Atrial Fibrillation/genetics , Atrial Fibrillation/epidemiology , Male , Female , Middle Aged , Cohort Studies , Weight Gain/genetics , Young Adult , Adult , Risk Factors , Weight Loss/genetics , Sweden/epidemiology , AgedABSTRACT
PURPOSE: The purpose of the study is to investigate female prisoners' perspectives on why they gain weight while in prison. DESIGN/METHODOLOGY/APPROACH: A qualitative design was used with semi-structured interviews with six females currently residing in a prison in the south of England. FINDINGS: Analysis of the data generated three themes relating to the reasons why women gain weight in prison. These were labelled as "The only thing you haven't got to ask permission for is your food, it's just handed to you", "If you've been stripped of the things that make you happy, or that you are addicted to, eating can soothe you" and "prison can make you take better care of your health". ORIGINALITY/VALUE: The results identify perceived reasons why women gain weight in prison uniquely from the female prisoner perspective. The implications of the research identify the need for systemic change throughout different prison departments to enable women to maintain a healthy weight during their custodial sentence.
Subject(s)
Prisoners , Weight Gain , Humans , Female , Prisoners/psychology , Adult , England , Qualitative Research , Interviews as Topic , Middle AgedABSTRACT
BACKGROUND/AIMS: This study is aimed to compare the effects of nutrition which has been enriched with different amounts of gluten to gluten-free diets on weight gain, diabetogenic state, hematological, and biochemical parameters. MATERIALS AND METHODS: A total of 40 newly weaned male Wistar albino rats used in the study were randomized into 4 different groups based on the gluten rations they were given. Following 12 weeks of diet they were killed and intracardiac blood samples were collected. Groups were identified as group 1 (n = 10): control group; normal rat ration containing wheat, group 2 (n = 10): gluten-free diet, group 3 (n = 10): ration containing medium level of gluten (normal rat diet+6% vital gluten) and group 4 (n = 10): ration containing high level of gluten (normal rat diet+12% vital gluten). RESULTS: In groups 3 and 4, high-density lipoprotein was found to be higher than the other 2groups. However, when group 2 results were compared to the other groups; the highest T3, T4, creatinine and B12 levels and the lowest gluten-specific IgE level were observed. alanine aminotransferase and aspartate aminotransferase levels were found to be higher in group 1 compared to the other 3 groups. No statistically significant difference was detected between the groups in terms of other parameters. CONCLUSION: This study provides evidence that a gluten-containing diet does not cause weight gain, has no diabetogenic effect, and also does not adversely affect general health in relation to hematological, biochemical, and various endocrinological parameters.
Subject(s)
Diet, Gluten-Free , Glutens , Rats, Wistar , Weight Gain , Animals , Male , Rats , Glutens/adverse effects , Immunoglobulin E/blood , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Creatinine/bloodABSTRACT
The term KgA1c paradox is used to describe the unwanted rise in weight that occurs when HbA1c is controlled using conventional therapy. We highlight facets of pathophysiology, prevention, pharmacology, person centred care, and epidemiology, which correspond to the concept of KgA1c paradox. We suggest a novel index, KgA1c product [(BMI) x (HbA1c)], which can be used to evaluate efficacy of drugs, and assess metabolic control in persons with diabetes.
Subject(s)
Glycated Hemoglobin , Hypoglycemic Agents , Humans , Glycated Hemoglobin/metabolism , Hypoglycemic Agents/therapeutic use , Body Mass Index , Diabetes Mellitus, Type 2 , Weight Gain/physiology , Diabetes Mellitus/epidemiologyABSTRACT
BACKGROUND: Antidepressants are among the most commonly prescribed medications, but evidence on comparative weight change for specific first-line treatments is limited. OBJECTIVE: To compare weight change across common first-line antidepressant treatments by emulating a target trial. DESIGN: Observational cohort study over 24 months. SETTING: Electronic health record (EHR) data from 2010 to 2019 across 8 U.S. health systems. PARTICIPANTS: 183 118 patients. MEASUREMENTS: Prescription data determined initiation of treatment with sertraline, citalopram, escitalopram, fluoxetine, paroxetine, bupropion, duloxetine, or venlafaxine. The investigators estimated the population-level effects of initiating each treatment, relative to sertraline, on mean weight change (primary) and the probability of gaining at least 5% of baseline weight (secondary) 6 months after initiation. Inverse probability weighting of repeated outcome marginal structural models was used to account for baseline confounding and informative outcome measurement. In secondary analyses, the effects of initiating and adhering to each treatment protocol were estimated. RESULTS: Compared with that for sertraline, estimated 6-month weight gain was higher for escitalopram (difference, 0.41 kg [95% CI, 0.31 to 0.52 kg]), paroxetine (difference, 0.37 kg [CI, 0.20 to 0.54 kg]), duloxetine (difference, 0.34 kg [CI, 0.22 to 0.44 kg]), venlafaxine (difference, 0.17 kg [CI, 0.03 to 0.31 kg]), and citalopram (difference, 0.12 kg [CI, 0.02 to 0.23 kg]); similar for fluoxetine (difference, -0.07 kg [CI, -0.19 to 0.04 kg]); and lower for bupropion (difference, -0.22 kg [CI, -0.33 to -0.12 kg]). Escitalopram, paroxetine, and duloxetine were associated with 10% to 15% higher risk for gaining at least 5% of baseline weight, whereas bupropion was associated with 15% reduced risk. When the effects of initiation and adherence were estimated, associations were stronger but had wider CIs. Six-month adherence ranged from 28% (duloxetine) to 41% (bupropion). LIMITATION: No data on medication dispensing, low medication adherence, incomplete data on adherence, and incomplete data on weight measures across time points. CONCLUSION: Small differences in mean weight change were found between 8 first-line antidepressants, with bupropion consistently showing the least weight gain, although adherence to medications over follow-up was low. Clinicians could consider potential weight gain when initiating antidepressant treatment. PRIMARY FUNDING SOURCE: National Institutes of Health.
Subject(s)
Antidepressive Agents , Weight Gain , Humans , Antidepressive Agents/therapeutic use , Antidepressive Agents/adverse effects , Female , Male , Weight Gain/drug effects , Middle Aged , Adult , Bupropion/therapeutic use , Bupropion/adverse effects , Citalopram/therapeutic use , Citalopram/adverse effects , Duloxetine Hydrochloride/therapeutic use , Duloxetine Hydrochloride/adverse effects , AgedABSTRACT
OBJECTIVE: This study aimed to determine a dopaminergic circuit required for diet-induced obesity in mice. METHODS: We created conditional deletion mutants for tyrosine hydroxylase (TH) using neurotensin receptor 1 (Ntsr1) Cre and other Cre drivers and measured feeding and body weight on standard and high-fat diets. We then used an adeno-associated virus to selectively restore TH to the ventral tegmental area (VTA) Ntsr1 neurons in conditional knockout (cKO) mice. RESULTS: Mice with cKO of Th using Vglut2-Cre, Cck-Cre, Calb1-Cre, and Bdnf-Cre were susceptible to obesity on a high-fat diet; however, Ntsr1-Cre Th cKO mice resisted weight gain on a high-fat diet and did not experience an increase in day eating unlike their wild-type littermate controls. Restoration of TH to the VTA Ntsr1 neurons of the Ntsr1-Cre Th cKO mice using an adeno-associated virus resulted in an increase in weight gain and day eating on a high-fat diet. CONCLUSIONS: Ntsr1-Cre Th cKO mice failed to increase day eating on a high-fat diet, offering a possible explanation for their resistance to diet-induced obesity. These results implicate VTA Ntsr1 dopamine neurons as promoting out-of-phase feeding behavior on a high-fat diet that could be an important contributor to diet-induced obesity in humans.
Subject(s)
Diet, High-Fat , Dopamine , Mice, Knockout , Obesity , Receptors, Neurotensin , Tyrosine 3-Monooxygenase , Ventral Tegmental Area , Weight Gain , Animals , Receptors, Neurotensin/metabolism , Receptors, Neurotensin/genetics , Obesity/metabolism , Obesity/etiology , Mice , Ventral Tegmental Area/metabolism , Dopamine/metabolism , Tyrosine 3-Monooxygenase/metabolism , Male , Neurons/metabolism , Dopaminergic Neurons/metabolism , Mice, Inbred C57BL , Dependovirus/genetics , Body WeightABSTRACT
AIMS: To determine risk factors for 1-year postpartum weight retention (PPWR) and glucose intolerance (prediabetes + diabetes) in women with a previous history of gestational diabetes (GDM) and prediabetes in early postpartum. METHODS: In this exploratory analysis of the MELINDA randomized controlled trial, we report data of 167 women with prediabetes at the 6-16 weeks (early) postpartum oral glucose tolerance test after a recent history of GDM. RESULTS: Of all participants, 45% (75) had PPWR >0 kg at 1-year postpartum. Compared to women without PPWR, women with PPWR had higher gestational weight gain [10.5 ± 6.4 vs. 6.5 ± 4.5 kg, p < 0.001], higher BMI (p < 0.01) and a worse metabolic profile (higher waist circumference, worse lipid profile and more insulin resistance) (all p < 0.05) both in early and late postpartum. Of all women with PPWR, 40.0% developed metabolic syndrome, compared to 18.9% of women without late PPWR (p = 0.003). The only independent predictor for late PPWR was weight retention in early postpartum (p < 0.001). Of all participants, 55.1% (92) had glucose intolerance (84 prediabetes, 8 diabetes) 1-year postpartum. Independent predictors for late postpartum glucose intolerance were lower gestational age at start insulin therapy in pregnancy and delivery by caesarean section (resp. p = 0.044 and 0.014). CONCLUSIONS: In women with a previous history of GDM and prediabetes in early postpartum, PPWR in early postpartum was a strong independent predictor for late PPWR, while earlier start of insulin therapy during pregnancy and delivery by caesarean section were independent predictors of glucose intolerance in late postpartum.
Subject(s)
Diabetes, Gestational , Glucose Intolerance , Glucose Tolerance Test , Postpartum Period , Prediabetic State , Humans , Female , Diabetes, Gestational/epidemiology , Diabetes, Gestational/metabolism , Pregnancy , Prediabetic State/epidemiology , Prediabetic State/metabolism , Adult , Glucose Intolerance/epidemiology , Glucose Intolerance/metabolism , Risk Factors , Gestational Weight Gain , Metabolic Syndrome/epidemiology , Body Mass Index , Weight Gain/physiologyABSTRACT
OBJECTIVE: Weight gain, blood lipids and/or glucose dysregulation can follow aripiprazole treatment onset. Whether aripiprazole dosage is associated with an increase in these metabolic parameters remains uncertain. The present study investigates aripiprazole dose associations with weight change, blood glucose, lipids, and blood pressure. METHODS: 422 patients taking aripiprazole for a minimum of three weeks to one year were selected from PsyMetab and PsyClin cohorts. Associations between aripiprazole dose and metabolic outcomes were examined using linear mixed-effect models. RESULTS: Aripiprazole dose was associated with weight change when considering its interaction with treatment duration (interaction term: -0.10, p < 0.001). This interaction resulted in greater weight gain for high versus low doses at the beginning of the treatment, this result being overturned at approximately five months, with greater weight increase for low versus high doses thereafter. LDL and HDL cholesterol levels were associated with aripiprazole dose over five months independently of treatment duration, with an average of 0.06 and 0.02 mmol/l increase for each 5 mg increment, respectively (p = 0.033 and p = 0.016, respectively). Furthermore, mean dose increases were associated with greater odds (+30 % per 5 mg increase) of clinically relevant weight gain (i.e., ≥7 %) over one year (p = 0.025). CONCLUSION: Aripiprazole dose was associated with one-year weight changes when considering its interaction with treatment duration. Increasing its dose could lead to metabolic worsening over the first five months of treatment, during which minimum effective doses should be particularly preferred.
Subject(s)
Antipsychotic Agents , Aripiprazole , Dose-Response Relationship, Drug , Weight Gain , Humans , Aripiprazole/adverse effects , Aripiprazole/administration & dosage , Male , Female , Antipsychotic Agents/adverse effects , Antipsychotic Agents/administration & dosage , Longitudinal Studies , Adult , Weight Gain/drug effects , Middle Aged , Blood Glucose/drug effects , Blood Glucose/metabolism , Blood Pressure/drug effects , Schizophrenia/drug therapy , Schizophrenia/blood , Lipids/bloodABSTRACT
This experiment evaluated the performance, health, and physiological responses of high-risk steers receiving a Bacillus-based probiotic during a 90-d grazing period. A total of 240 Angus-influenced steers were used in this experiment that was replicated over 2 yr (120 steers/year). Each year, steers were obtained from an auction yard and transported to the experimental facility (120 km). Steer body weight (BW) was recorded at arrival (day -1), and this value was averaged with BW recorded on day 0 to represent the initial BW (236.6 ± 1.5 kg). On day 0, steers were ranked by BW and allocated to 1 of 12 pastures with stockpiled native grass (4-ha pastures; 10 steers/pasture). Pastures were randomly assigned to receive daily supplementation with dried distillers' grains at 1% of BW containing either: 1) Bacillus subtilisâ +â B. licheniformis probiotic (BOV; 2 g/steer daily of Bovacillus; Novonesis, Horsholm, Denmark) or 2) no feed additive (CON). Cattle received treatments from days 0 to 90, in addition to free-choice access to water and mineralâ +â vitamin mix without ionophore. Steers were assessed for bovine respiratory disease (BRD) signs daily. Blood samples were collected and full BW was recorded on days 0, 14, 28, 56, and 90. Shrunk BW was recorded on day 91 after 16 h of feed and water restriction, and a 4% pencil shrink was used to calculate the final BW. Average daily gain (ADG) was calculated based on initial and final BW. No treatment effects were detected (Pâ ≥â 0.73) for steer final BW and ADG. A treatmentâ ×â day interaction was detected (Pâ ≤â 0.05) for plasma haptoglobin concentration, which was greater for CON steers on days 14 and 28 (Pâ ≤â 0.02). Incidence of BRD signs did not differ (Pâ =â 0.97) between treatments (51.7% and 51.3% for BOV and CON, respectively; SEMâ =â 7.70). However, steer mortalityâ +â removals for health complications were greater (Pâ =â 0.01) in CON compared to BOV (0.00% vs. 5.04%, respectively; SEMâ =â 1.41). Supplementing BOV improved (Pâ ≤â 0.04) total pasture-based liveweight change (643 vs. 502 kg/pasture, respectively; SEMâ =â 45) and final pasture-based total liveweight (3,007 vs. 2,869 kg/pasture, respectively; SEMâ =â 46). Collectively, supplementation with a probiotic based on B. subtilis and B. licheniformis to high-risk stocker cattle did not alleviate the incidence of BRD signs nor improved ADG, but decreased acute-phase protein response, reduced steer mortalityâ +â removal, and increased pasture-based productivity during a 90-d grazing period.
Stocker cattle are exposed to several stressors within a short period of time, which impair their immunity and lead to bovine respiratory disease (BRD). With the increased regulations regarding the use of antimicrobials in cattle nutrition, novel dietary strategies to improve health and productivity of stocker cattle are warranted. One example is supplementing Bacillus-based probiotics, which promote performance and immunity in high-stress cattle. In this study, steers were purchased from a commercial auction yard soon after weaning, transported to the research facility, and assigned initial processing within a 48-h period. Steers were assigned to pastures and were supplemented or not with the Bacillus-based probiotic during a 90-d grazing period. In general, supplementing steers with the Bacillus-based probiotic did not impact growth rates or BRD incidence. However, no steers that received the Bacillus-based probiotic died from BRD consequences nor were removed from the experiment due to health reasons, whereas 5% of unsupplemented steers did not complete the 90-d experiment. Consequently, pasture-based liveweight gain was increased by 28% due to Bacillus-based probiotic supplementation. Results from this study indicate that supplementing a B. subtilisâ +â B. licheniformis probiotic could be an alternative to improve the health and overall productivity of high-risk stocker cattle.